Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
← catalyst calendarNCT07780968 · readout in 1,863 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
300estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-01 | estimated | When the study began enrolling |
| Primary completion | 2031-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Esophageal Cancer
- GastroEsophageal Cancer
- Gastroesophageal-junction Cancer
- HER2-positive Gastric Cancer
- Stomach Cancer
Intervention
- Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
Primary outcomes
what the primary-completion date above is the date OFAverage age of participants
measured Baseline
Patient demographics
measured Baseline
Clinical characteristics
measured Baseline
Average BMI
measured Baseline
Average BSA
measured Baseline
Heart Function
measured Baseline
Diagnostic history
measured Baseline
Treatment history
measured Baseline
Biomarkers
measured Baseline
Number of participants taking a treatment in combination with first line zanidatamab-containing therapy
measured Up to 5 years
Average dose of treatment
measured Up to 5 years
Cycles of treatment
measured Up to 5 years
Average duration of first line zanidatamab-containing therapy
measured Up to 5 years
Number of participants at each HER2 status results after initiation of first line zanidatamab-containing therapy
measured Up to 5 years
Average chemotherapy dose adjustment
measured Up to 5 years
Duration of treatment interruption
measured Up to 5 years
Number of participants at each subsequent line of therapy after treatment discontinuation
measured Up to 5 years
Reason of treatment adjustment
measured Up to 5 years
Related
JAZZ · their whole pipeline · Esophageal Cancer readouts
JAZZ's other studiesmost recently updated first
- A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Phase 4 · Not yet recruiting
- Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy — · Recruiting
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH Phase 3 · Recruiting
- A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures Phase 1 · Recruiting
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma Phase 2 · Recruiting
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed